Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old
| Autor: | Lynn M. Rundhaugen, Chadi Nabhan, Mary Beth Riley, Simrit Parmar, John L. Frater, Adekunle Raji, Martin S. Tallman, Larry Boehlke |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty ATP Binding Cassette Transporter Subfamily B Arsenicals chemistry.chemical_compound Arsenic Trioxide Refractory Internal medicine medicine Humans Arsenic trioxide Adverse effect Aged Glycoproteins Aged 80 and over Salvage Therapy medicine.diagnostic_test business.industry Myeloid leukemia Bone Marrow Examination Neoplasms Second Primary Oxides Hematology Middle Aged medicine.disease Drug Resistance Multiple Surgery Clinical trial Bone marrow examination Leukemia Treatment Outcome chemistry Leukemia Myeloid Acute Disease Disease Progression Female business Progressive disease |
| Zdroj: | Leukemia Research. 28:909-919 |
| ISSN: | 0145-2126 |
| Popis: | The prognosis for patients with relapsed/refractory AML, secondary leukemia and AML in older adults is extremely poor. An appealing alternative approach to intensive cytotoxic chemotherapy is to induce apoptosis with a novel agent. There is in vitro evidence that arsenic trioxide (ATO) has anti-proliferative and pro-apoptotic effects on myeloid leukemia cell lines. To evaluate efficacy and toxicities of ATO, we conducted a phase II trial including subjects with relapsed/refractory or secondary AML or age > or = 65 years with de novo disease. Eleven subjects were entered with a median age of 77 years (56-90) and a median total dose of ATO of 415.55 mg (91.5-793) with a daily dose of 0.25 mg/kg. Median survival following the first dose of ATO was 2.25 months (0.4-19). Myelosuppression was the major adverse effect, most likely due to disease progression rather than drug-related. All subjects had progressive disease. There was no direct treatment-related mortality. Based on this study, we do not recommend single agent ATO as a treatment option for AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect